SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : JMAR Technologies(JMAR) -- Ignore unavailable to you. Want to Upgrade?

To: henry jakala who wrote (4465)12/14/1997 11:11:00 AM
From: Bilberry  Respond to of 9695
 
Thanks for the article Henry. One of the blurbs in there showed why an x-ray source (such as JMAR's) would enhance X-ray over just using a synchotron, since it would take away the disadvantage noted below.

Lucent will now take orders for Scalpel at $8 million per system. Noting that X-ray lithography requires an SOR ring with multiple steppers, Boulin said that Scalpel has "none of the granularity issues associated with X-ray. For Scalpel, if you need to add another stepper, just buy one for another $8 million."

--Bilberry



To: henry jakala who wrote (4465)12/14/1997 11:14:00 AM
From: Richaaard  Read Replies (1) | Respond to of 9695
 
Henry,
I wonder who the 10 partners are that are referred to in that Lucent group. I hope JMAR is one of them. These other companies appear to be getting antsy with regards to the IBM advantage.

Off Topic: Interesting attempted buyout on SOSA, it may be a good buy now. This attempted sale will probably be shot down and the real bidding may start.

Richard


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News